Technology is reshaping nearly every stage of healthcare, from the moment a doctor reads your scan to the way you refill a prescription from your phone. The changes are measurable: AI tools now help radiologists catch cancers they’d otherwise miss, remote monitoring programs have cut emergency room visits by more than half for high-risk patients, and the FDA has authorized over 1,400 AI-enabled medical devices for use in the United States. Here’s where technology is making the biggest practical difference.
AI-Assisted Diagnosis
One of the clearest wins for technology in healthcare is helping clinicians read medical images more accurately. A systematic review of AI-assisted radiology in cancer detection found that when doctors used AI tools alongside their own judgment, their sensitivity (the ability to correctly identify disease) jumped from 66% to 79%, while specificity (correctly ruling out disease) rose from 82% to 87%. In plain terms, AI assistance helped doctors catch more real cancers while also reducing false alarms.
The improvement varies by imaging type. AI-assisted CT scans reached 89% sensitivity for cancer detection. MRI studies saw one of the most dramatic gains: sensitivity climbed from 71% without AI to 87% with it. These tools don’t replace radiologists. They act as a second set of eyes, flagging areas of concern that a busy clinician scanning dozens of images per shift might overlook. As of early 2026, the FDA lists 1,430 AI-enabled medical devices authorized for the U.S. market, the majority of them in radiology.
Remote Monitoring and Telemedicine
For patients recently discharged from the hospital, the weeks that follow are a vulnerable window. Remote health monitoring, where patients use connected devices at home to transmit vital signs to a care team, is proving effective at keeping people out of the ER during that period. In a prospective study of high-risk patients, average hospitalizations dropped from 0.45 to 0.19 per patient within three months of starting remote monitoring. Emergency department visits fell even more sharply, from 0.48 to just 0.06 per patient in the same timeframe.
At the six-month mark, the benefits held. Average hospitalizations fell from 0.55 to 0.23, and ED visits dropped by more than half. The practical effect is significant: fewer trips back to the hospital means less disruption to recovery, lower out-of-pocket costs, and reduced strain on an already stretched system. These programs typically involve daily check-ins through a tablet or app, with a nurse reviewing the data and calling the patient if anything looks off. It’s a relatively simple intervention with outsized results for people managing heart failure, COPD, or other conditions that frequently trigger readmissions.
Wearable Devices and Early Detection
Consumer wearables have moved well beyond step counting. Smartwatches can now screen for atrial fibrillation, an irregular heart rhythm that raises the risk of stroke fivefold. In a controlled study of 51 patients, a deep neural network analyzing Apple Watch heart rate data detected atrial fibrillation with 98% sensitivity and 90.2% specificity. That’s remarkably accurate for a device on your wrist.
Real-world performance is more modest. When the same algorithm was tested on over 1,600 people going about their daily lives, sensitivity and specificity both dropped to around 68%. Movement, poor sensor contact, and the low prevalence of atrial fibrillation in the general population all reduce accuracy outside a clinical setting. Still, wearables serve as an effective screening layer. They won’t replace an EKG, but they can prompt someone who has no symptoms to seek evaluation, catching a condition that often goes undiagnosed until a stroke occurs.
Robotic-Assisted Surgery
Surgical robots give surgeons magnified, three-dimensional views of the operating field and instruments that can rotate in ways the human wrist cannot. The result, according to Mayo Clinic, is that patients who undergo robotic procedures typically have shorter hospital stays and return to normal function faster than those who have traditional open or laparoscopic surgery. The advantages are most pronounced in procedures involving tight spaces, like prostate removal or certain gynecological surgeries, where the robot’s precision reduces damage to surrounding tissue.
For the patient, this translates to smaller incisions (usually a few puncture sites rather than a long cut), less post-operative pain, and a quicker return to work and daily activities. Not every surgery benefits equally from the robotic approach, and the technology adds cost to a procedure. But for the operations where it fits, the recovery difference is meaningful.
Patient Portals and Medication Adherence
Something as simple as giving patients digital access to their health records changes behavior. A large study of adults with diabetes found that patients who gained access to both a computer and mobile patient portal took their oral diabetes medications more consistently, with a 1.67 percentage point increase in the share of days they took their pills as prescribed. Their blood sugar control improved modestly as well, with a small but statistically significant drop in HbA1c levels.
The effect was strongest for people who needed it most. Among patients whose diabetes was poorly controlled at baseline (HbA1c above 8.0%), gaining portal access was associated with a 5.09 percentage point increase in medication adherence and a more meaningful HbA1c reduction. The mechanism is straightforward: when you can see your lab results, upcoming appointments, and prescription details on your phone, you’re more engaged in managing your own care. You notice when a refill is due. You see how your numbers change over time. That visibility nudges people toward consistency.
Cutting Administrative Waste
A less visible but enormous impact of technology in healthcare is reducing the administrative burden that inflates costs across the system. Billing, prior authorizations, claims processing, and scheduling consume a staggering share of healthcare spending in the United States. An analysis by Oliver Wyman estimates that optimizing these administrative processes could save the healthcare industry $450 billion over the next decade. Of that, roughly $125 billion would come from reducing internal business costs, while another $325 billion could be unlocked by simplifying processes between payers, providers, and patients.
Automation handles much of the repetitive work that currently requires human labor: verifying insurance eligibility, submitting claims, flagging coding errors before they trigger denials. Natural language processing can extract relevant information from clinical notes and route it to the right form. These tools don’t eliminate administrative staff, but they free up time for the work that requires human judgment, like resolving complex billing disputes or coordinating care across providers. For patients, the downstream effect is shorter wait times, fewer surprise bills caused by coding mistakes, and a system that spends more of every dollar on actual care.
Genomics and Targeted Treatment
Genomic sequencing allows oncologists to identify specific mutations driving a patient’s cancer and match them with drugs designed to target those mutations. The promise is significant: instead of broad chemotherapy that attacks all fast-dividing cells, a patient could receive a targeted therapy aimed at the molecular flaw in their tumor. This approach has produced dramatic responses in certain cancers, particularly lung cancers with specific driver mutations like EGFR or ALK alterations, where targeted drugs are now standard first-line treatment.
The broader picture is more nuanced. A study of advanced non-small cell lung cancer patients in community oncology settings found no statistically significant difference in 12-month mortality between those who received broad genomic sequencing and those who had routine testing (41.1% vs. 44.4% predicted probability of death). This doesn’t mean genomic testing is useless. It means the benefits concentrate in patients whose tumors harbor actionable mutations, perhaps 30 to 40% of cases depending on cancer type. For those patients, targeted therapy can be transformative. For the rest, sequencing may not yet change outcomes. The technology’s value is real but specific, and it works best when integrated into treatment decisions early.